The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Open accessAbstract
BACKGROUND: Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a response to prior interferon treatment, currently have no approved treatment options. In phase 2 trials, regimens including the oral nucleotide polymerase inhibitor sofosbuvir have shown efficacy in patients with HCV genotype 2 or 3 infection. METHODS: We conducted two randomized, phase 3 studies involving patients with chronic HCV genotype 2 or 3 infection. In one trial, patients for whom treatment with peginterferon was not an option received oral sofosbuvir and ribavirin (207 patients) or matching placebo (71) for 12 weeks. In a second trial, patients who had not had a response to prior interferon therapy received sofosbuvir and ribavirin for 12 weeks (103 patients) or 16 weeks (98). The primary end point was a sustained virologic response at 12 weeks after therapy. RESULTS: Among patients for whom treatment with peginterferon was not an option, the rate of a sustained virologic response was 78% (95% confidence interval [CI], 72 to 83) with sofosbuvir and ribavirin, as compared with 0% with placebo (P<0.001). Among previously treated patients, the rate of response was 50% with 12 weeks of treatment, as compared with 73% with 16 weeks of treatment (difference, -23 percentage points; 95% CI, -35 to -11; P<0.001). In both studies, response rates were lower among patients with genotype 3 infection than among those with genotype 2 infection and, among patients with genotype 3 infection, lower among those with cirrhosis than among those without cirrhosis. The most common adverse events were headache, fatigue, nausea, and insomnia; the overall rate of discontinuation of sofosbuvir was low (1 to 2%). CONCLUSIONS: In patients with HCV genotype 2 or 3 infection for whom treatment with peginterferon and ribavirin was not an option, 12 or 16 weeks of treatment with sofosbuvir and ribavirin was effective. Efficacy was increased among patients with HCV genotype 2 infection and those without cirrhosis. In previously treated patients with genotype 3 infection, 16 weeks of therapy was significantly more effective than 12 weeks. (Funded by Gilead Sciences; POSITRON and FUSION ClinicalTrials.gov numbers, NCT01542788 and NCT01604850, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Self-citationMcHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Self-citationDiagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Holland, P. M., Abramson, R. D., Watson, R., & Gelfand, D. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.16.7276 · Cited by 2,693
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
Self-citationPeginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3
Mangia, A., Santoro, R., Minerva, N., Ricci, G. L., Carretta, V., Persico, M., Vinelli, F., Scotto, G., Bacca, D., Annese, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042608 · Cited by 840
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Symonds, W. T., Hindes, R. G., & Berrey, M. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208953 · Cited by 764
Self-citationPeginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3
Shiffman, M. L., Suter, F., Bacon, B. R., Nelson, D., Harley, H., Solá, R., Shafran, S. D., Barange, K., Lin, A., Soman, A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066403 · Cited by 493
Self-citationSurprisingly Small Effect of Antiviral Treatment in Patients with Hepatitis C
Falck-Ytter, Y., Kale, H., Mullen, K. D., Sarbah, S. A., Sorescu, L., & McCullough, A. J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-4-200202190-00008 · Cited by 301
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
Sulkowski, M., Cooper, C., Hunyady, B., Jia, J., Ogurtsov, P. P., Peck‐Radosavljevic, M., Shiffman, M. L., Yurdaydın, C., & Dalgård, O. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.21 · Cited by 175
Self-citation
Cited by
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., Romero-Gomez, M., Zarski, J.-P., Agarwal, K., Buggisch, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402454 · Cited by 1,705
Self-citationGlobal distribution and prevalence of hepatitis C virus genotypes
Messina, J. P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G. S., Pybus, O. G., & Barnes, E. (2015) · Hepatology · doi:10.1002/hep.27259 · Cited by 1,589
Panel, A. H. G. (2015) · Hepatology · doi:10.1002/hep.27950 · Cited by 1,382
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A. S., Hinestrosa, F., Thuluvath, P. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306218 · Cited by 1,190
Self-citationEASL Recommendations on Treatment of Hepatitis C 2015
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.025 · Cited by 1,156
Ghany, M. G., Morgan, T. R., & Panel, A. H. C. G. (2020) · Hepatology · doi:10.1002/hep.31060 · Cited by 955
Petruzziello, A., Marigliano, S., Loquercio, G., Cozzolino, A., & Cacciapuoti, C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i34.7824 · Cited by 864
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Zeuzem, S., Dusheiko, G. M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R. H., Illeperuma, A., Svarovskaia, E., Brainard, D. M., Symonds, W. T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316145 · Cited by 795
Self-citationNelson, D. R., Cooper, J. N., Lalezari, J. P., Lawitz, E., Pockros, P. J., Gitlin, N., Freilich, B. F., Younes, Z. H., Harlan, W., Ghalib, R., et al. (2015) · Hepatology · doi:10.1002/hep.27726 · Cited by 689
Self-citationWilliams, R., Aspinall, R., Bellis, M., Camps-Walsh, G., Cramp, M., Dhawan, A., Ferguson, J., Forton, D., Foster, G., Gilmore, S. I., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61838-9 · Cited by 602
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
Scheel, T. K. H., & Rice, C. M. (2013) · Nature Medicine · doi:10.1038/nm.3248 · Cited by 554
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Pawlotsky, J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.003 · Cited by 518
Current and Future Therapies for Hepatitis C Virus Infection
Liang, T. J., & Ghany, M. G. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1213651 · Cited by 490
Webster, D. P., Klenerman, P., & Dusheiko, G. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62401-6 · Cited by 439
Treatment of Hepatitis C: A Systematic Review
Kohli, A., Shaffer, A., Sherman, A., & Kottilil, S. (2014) · JAMA · doi:10.1001/jama.2014.7085 · Cited by 426
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
Bartenschlager, R., Lohmann, V., & Penin, F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3046 · Cited by 402
Barua, S., Greenwald, R., Grebely, J., Dore, G. J., Swan, T., & Taylor, L. E. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0406 · Cited by 401
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
Gane, E., Lawitz, E., Pugatch, D., Papatheodoridis, G., Bräu, N., Brown, A., Pol, S., Leroy, V., Persico, M., Moreno, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704053 · Cited by 400
Self-citationChhatwal, J., Kanwal, F., Roberts, M. S., & Dunn, M. A. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1336 · Cited by 338
Curry, M. P., Forns, X., Chung, R. T., Terrault, N. A., Brown, R., Fenkel, J. M., Gordon, F., O’Leary, J., Kuo, A., Schiano, T., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.023 · Cited by 334
Self-citationFrom non-A, non-B hepatitis to hepatitis C virus cure
Pawlotsky, J.-M., Feld, J. J., Zeuzem, S., & Hoofnagle, J. H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.006 · Cited by 328
Self-citationKanwal, F., Kramer, J. R., Ilyas, J., Duan, Z., & El-Serag, H. B. (2014) · Hepatology · doi:10.1002/hep.27095 · Cited by 322
Koh, C., Li, Q., & Liang, J. (2016) · Clinical Virology · doi:10.1128/9781555819439.ch54 · Cited by 321
Cell and tissue engineering for liver disease
Bhatia, S. N., Underhill, G. H., Zaret, K. S., & Fox, I. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3005975 · Cited by 309
Durand, C. M., Bowring, M. G., Brown, D. M., Chattergoon, M. A., Massaccesi, G., Bair, N., Wesson, R., Reyad, A., Naqvi, F. F., Ostrander, D., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2871 · Cited by 302
Self-citationYates, M. K., & Seley-Radtke, K. L. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2018.11.016 · Cited by 275
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
Sulkowski, M. S., Naggie, S., Lalezari, J., Fessel, W. J., Mounzer, K., Shuhart, M., Luetkemeyer, A. F., Asmuth, D., Gaggar, A., Ni, L., et al. (2014) · JAMA · doi:10.1001/jama.2014.7734 · Cited by 254
Self-citationHill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu012 · Cited by 216
“Sofosbuvir + RBV POSITRON [15] (n = 207 + 71 placebo) IFN-ineligible 2 12 wk (n = 109) 93% (SVR-12)”
Linas, B. P., Barter, D. M., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1313 · Cited by 101
“In combination with ribavirin, sofosbuvir can be used to treat patients with chronic HCV genotype 2 or 3 infection without interferon, yielding cure rates greater than with the previous standard of care (2, 3).”
Advances in hepatitis C therapy: what is the current state - what come's next?
Zopf, S. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i3.139 · Cited by 91
Dieperink, E., Fuller, B., Isenhart, C., McMaken, K., Lenox, R., Pocha, C., Thuras, P., & Hauser, P. (2014) · Addiction · doi:10.1111/add.12679 · Cited by 45
Incorporating Patient-Reported Outcomes Into Hepatitis C Virus Treatment Studies
Evon, D. M. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.02.017 · Cited by 4
Metadata
- Authors
- Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., Schiff, E., Al-Assi, M. T., Subramanian, G. M., An, D., Lin, M., McNally, J., Brainard, D., Symonds, W. T., McHutchison, J. G., Patel, K., Feld, J., Pianko, S., & Nelson, D. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-05-16
- Volume
- 368
- Issue
- 20
- Pages
- 1867-1877
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2120733999
- Cited by
- 1,090
- References
- 10
- FWCI
- 131.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.